Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors
Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing…
PLN Reaffirms Commitment to Advancing a Just Energy Transition at COP30
Kyrgyz Republic Launches First Issuance of Gold-Backed Stablecoin USDKG
OMP Miami Conference 2025: Transforming Supply Chain Vision into REAL Impact with Human-AI Synergy
Doubleview Gold Corp. Highlights Scandium Potential at Hat Project, a Key Enabler for the Electrification Economy
U.S. Polo Assn. Receives Multiple Global Honors Recognizing Excellence in Brand, Content, and Digital Growth